{
  "first_published_at": "2014-05-30", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON418519", 
  "title": "Voriconazole: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinomaâ€”test liver function before and during treatment and tell patients to avoid sunlight exposure", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 27, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Voriconazole: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma&#8212;test liver function before and during treatment and tell patients to avoid sunlight exposure</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>Voriconazole (Vfend) is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin. Test liver function before starting treatment with voriconazole and at least weekly during the first month of treatment. Tell patients to avoid sunlight exposure while taking voriconazole. New tools to help monitor and manage these risks are being distributed</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Voriconazole (Vfend) is an antifungal medicine indicated for certain worsening, possibly life-threatening fungal infections in adults and children aged over 2 years. Voriconazole is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin.</p>\n\n<p>In clinical trials, some participants had serious hepatic reactions while taking voriconazole (including hepatitis and fulminant hepatic failure), some of which were fatal. Most of these reactions were in people with serious underlying medical conditions. Transient hepatic reactions (eg, jaundice, high liver enzyme levels) have occurred in people who took voriconazole but had no other risk factors. Liver function usually reverts to normal once voriconazole is stopped.</p>\n\n<p>We have received 1 Yellow Card report of a hepatic disorder and 3 Yellow Card reports of skin disorders in people taking voriconazole in the past 12 months, none of which were fatal (this rate is similar to previous years).</p>\n\n<p>The manufacturer is distributing tools to increase awareness and improve the monitoring and management of these risks. These include a healthcare professionals&#8217; Q&#38;A brochure, healthcare professionals&#8217; checklist, and patient alert card (please see below). As with all anti-infective treatments, consider official guidance on appropriate use when prescribing voriconazole.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<p>The advice below applies to both adults and children taking voriconazole.</p>\n\n<p><em>Liver toxicity</em></p>\n\n<ul>\n<li>Test liver function before starting treatment with voriconazole (specifically, aspartate transaminase [AST] and alanine transaminase [ALT] levels).</li>\n\n<li>Continue testing liver function at least weekly for the first month of treatment and monthly thereafter if there are no changes in the first month of treatment.</li>\n\n<li>Stop voriconazole if AST or ALT levels become markedly elevated, unless you consider the benefits of voriconazole treatment to outweigh the risk of liver toxicity in that individual.</li>\n</ul>\n\n<p><em>Phototoxicity and squamous cell carcinoma</em></p>\n\n<ul>\n<li>Tell patients to avoid sunlight exposure while taking voriconazole. Advise patients to wear protective clothing and use sunscreen with a high sun protection factor if in sunlight.</li>\n\n<li>Refer patients with phototoxic reactions to a dermatologist and consider stopping voriconazole treatment.</li>\n\n<li>If voriconazole is continued despite a phototoxic reaction, check the skin frequently and thoroughly to detect and manage pre-cancerous lesions as early as possible.</li>\n\n<li>Stop voriconazole if pre-cancerous skin lesions or squamous cell carcinoma are identified. Note that patients may develop squamous cell carcinoma without a prior phototoxic reaction.</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON426912\">Letter sent to healthcare professionals in April 2014</a></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON456015\">Letter sent to healthcare professionals in Sept 2014 (added post-publication)</a></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON418527\">Healthcare professionals&#8217; question and answer brochure</a></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON418526\">Healthcare professionals&#8217; checklist</a></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON457621\">Patient alert card</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP3709-voriconazole.htm\">BNF section 5.1: Antifungal drugs</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm\">Product information on voriconazole</a></p>\n\n<p><strong>Call for reporting</strong></p>\n\n<p>Please report suspected side effects of any medicine or vaccine to the MHRA through the Yellow Card Scheme online at <a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>. When reporting please ensure to include the name of the specific product administered.</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 10, May 2014: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\r\n\r\n\t\t\t\t\t\r\n\r\n\t\t\t\t\t\r\n\r\n\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n\t\t\r\n\t\t\r\n\t\t\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Voriconazole (Vfend) is an antifungal medicine indicated for certain worsening, possibly life-threatening fungal infections in adults and children aged over 2 years. Voriconazole is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin.</p>\n\n<p>In clinical trials, some participants had serious hepatic reactions while taking voriconazole (including hepatitis and fulminant hepatic failure), some of which were fatal. Most of these reactions were in people with serious underlying medical conditions. Transient hepatic reactions (eg, jaundice, high liver enzyme levels) have occurred in people who took voriconazole but had no other risk factors. Liver function usually reverts to normal once voriconazole is stopped.</p>\n\n<p>We have received 1 Yellow Card report of a hepatic disorder and 3 Yellow Card reports of skin disorders in people taking voriconazole in the past 12 months, none of which were fatal (this rate is similar to previous years).</p>\n\n<p>The manufacturer is distributing tools to increase awareness and improve the monitoring and management of these risks. These include a healthcare professionals&#8217; Q&amp;A brochure, healthcare professionals&#8217; checklist, and patient alert card (please see below). As with all anti-infective treatments, consider official guidance on appropriate use when prescribing voriconazole.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<p>The advice below applies to both adults and children taking voriconazole.</p>\n\n<p><em>Liver toxicity</em></p>\n\n<ul>\n<li>Test liver function before starting treatment with voriconazole (specifically, aspartate transaminase [AST] and alanine transaminase [ALT] levels).</li>\n\n<li>Continue testing liver function at least weekly for the first month of treatment and monthly thereafter if there are no changes in the first month of treatment.</li>\n\n<li>Stop voriconazole if AST or ALT levels become markedly elevated, unless you consider the benefits of voriconazole treatment to outweigh the risk of liver toxicity in that individual.</li>\n</ul>\n\n<p><em>Phototoxicity and squamous cell carcinoma</em></p>\n\n<ul>\n<li>Tell patients to avoid sunlight exposure while taking voriconazole. Advise patients to wear protective clothing and use sunscreen with a high sun protection factor if in sunlight.</li>\n\n<li>Refer patients with phototoxic reactions to a dermatologist and consider stopping voriconazole treatment.</li>\n\n<li>If voriconazole is continued despite a phototoxic reaction, check the skin frequently and thoroughly to detect and manage pre-cancerous lesions as early as possible.</li>\n\n<li>Stop voriconazole if pre-cancerous skin lesions or squamous cell carcinoma are identified. Note that patients may develop squamous cell carcinoma without a prior phototoxic reaction.</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con426912.pdf\" target='new\"\"'>Letter sent to healthcare professionals in April 2014<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (131Kb)</p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con456015.pdf\" target='new\"\"'>Letter sent to healthcare professionals in Sept 2014 (added post-publication)<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (95Kb)</p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con418527.pdf\" target='new\"\"'>Healthcare professionals&#8217; question and answer brochure<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (140Kb)</p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con418526.pdf\" target='new\"\"'>Healthcare professionals&#8217; checklist<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (105Kb)</p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con457621.pdf\" target='new\"\"'>Patient alert card<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (41Kb)</p>\n\n<p><a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP3709-voriconazole.htm\">BNF section 5.1: Antifungal drugs</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm\">Product information on voriconazole</a></p>\n\n<p><strong>Call for reporting</strong></p>\n\n<p>Please report suspected side effects of any medicine or vaccine to the MHRA through the Yellow Card Scheme online at <a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>. When reporting please ensure to include the name of the specific product administered.</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 10, May 2014: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-05-01", 
  "date_last_modified": "2014-09-22", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Letter sent to healthcare professionals in April 2014", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con426912.pdf", 
      "filename": "downloads/573c9f789743e8c170b7829e4ecbea431b09c14c/con426912.pdf", 
      "original_filename": "con426912.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Letter sent to healthcare professionals in Sept 2014 (added post-publication)", 
      "assetid": 1, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con456015.pdf", 
      "filename": "downloads/c0524b1e7f91efeceb0dcbfe5fccd00f487a4379/con456015.pdf", 
      "original_filename": "con456015.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Healthcare professionalsâ€™ question and answer brochure", 
      "assetid": 2, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con418527.pdf", 
      "filename": "downloads/b0c322178f40af6651808ec37da70ec5f067abec/con418527.pdf", 
      "original_filename": "con418527.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Healthcare professionalsâ€™ checklist", 
      "assetid": 3, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con418526.pdf", 
      "filename": "downloads/5b8bd904df3528a758069afaa7a52034a9678bf3/con418526.pdf", 
      "original_filename": "con418526.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Patient alert card", 
      "assetid": 4, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con457621.pdf", 
      "filename": "downloads/bb2a0e3b8a034914931082045615c3269810d4a9/con457621.pdf", 
      "original_filename": "con457621.pdf"
    }
  ], 
  "_item_id": 27, 
  "summary": "Voriconazole (Vfend) is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin. Test liver function before starting treatment with voriconazole and at least weekly during the first month of treatment. Tell patients to avoid sunlight exposure while taking voriconazole. New tools to help monitor and manage these risks are being distributed", 
  "body": "Article date: May 2014\n\nVoriconazole (Vfend) is an antifungal medicine indicated for certain worsening, possibly life-threatening fungal infections in adults and children aged over 2 years. Voriconazole is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin.\n\nIn clinical trials, some participants had serious hepatic reactions while taking voriconazole (including hepatitis and fulminant hepatic failure), some of which were fatal. Most of these reactions were in people with serious underlying medical conditions. Transient hepatic reactions (eg, jaundice, high liver enzyme levels) have occurred in people who took voriconazole but had no other risk factors. Liver function usually reverts to normal once voriconazole is stopped.\n\nWe have received 1 Yellow Card report of a hepatic disorder and 3 Yellow Card reports of skin disorders in people taking voriconazole in the past 12 months, none of which were fatal (this rate is similar to previous years).\n\nThe manufacturer is distributing tools to increase awareness and improve the monitoring and management of these risks. These include a healthcare professionalsâ€™ Q&A brochure, healthcare professionalsâ€™ checklist, and patient alert card (please see below). As with all anti-infective treatments, consider official guidance on appropriate use when prescribing voriconazole.\n\nAdvice for healthcare professionals:\n\nThe advice below applies to both adults and children taking voriconazole.\n\nLiver toxicity  \n  \n  * Test liver function before starting treatment with voriconazole (specifically, aspartate transaminase [AST] and alanine transaminase [ALT] levels).  \n  * Continue testing liver function at least weekly for the first month of treatment and monthly thereafter if there are no changes in the first month of treatment.  \n  * Stop voriconazole if AST or ALT levels become markedly elevated, unless you consider the benefits of voriconazole treatment to outweigh the risk of liver toxicity in that individual.  \n  \nPhototoxicity and squamous cell carcinoma  \n  \n  * Tell patients to avoid sunlight exposure while taking voriconazole. Advise patients to wear protective clothing and use sunscreen with a high sun protection factor if in sunlight.  \n  * Refer patients with phototoxic reactions to a dermatologist and consider stopping voriconazole treatment.  \n  * If voriconazole is continued despite a phototoxic reaction, check the skin frequently and thoroughly to detect and manage pre-cancerous lesions as early as possible.  \n  * Stop voriconazole if pre-cancerous skin lesions or squamous cell carcinoma are identified. Note that patients may develop squamous cell carcinoma without a prior phototoxic reaction.  \n  \nFurther information:\n\n[ASSET_TAG](#ASSET0) (131Kb)\n\n[ASSET_TAG](#ASSET1) (95Kb)\n\n[ASSET_TAG](#ASSET2) (140Kb)\n\n[ASSET_TAG](#ASSET3) (105Kb)\n\n[ASSET_TAG](#ASSET4) (41Kb)\n\n[BNF section 5.1: Antifungal drugs](http://www.medicinescomplete.com/mc/bnf/current/PHP3709-voriconazole.htm)\n\n[Product information on voriconazole](http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm)\n\nCall for reporting\n\nPlease report suspected side effects of any medicine or vaccine to the MHRA through the Yellow Card Scheme online at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). When reporting please ensure to include the name of the specific product administered.\n\nArticle citation: Drug Safety Update volume 7 issue 10, May 2014: A2.\n"
}